

April 26, 2025

<b>DCS-CRD</b> <b>BSE Limited</b> First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039  Stock Code: 543213	<b>Listing Compliance</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238  Stock Code: ROSSARI
--	--

Dear Sir/Madam,

**Subject.: Q4 & FY25 Press Release**

Please find enclosed a copy of the Press Release for the Quarter and Financial Year ended March 31, 2025.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,

**For Rossari Biotech Limited**

**Parul  
Gupta**

Digitally signed  
by Parul Gupta  
Date: 2025.04.26  
22:51:32 +05'30'



Parul Gupta

**Head - Company Secretary & Legal**

Membership No.: A38895

Encl.: as above

## ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

**Regd. Office:** Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

**Factory :** Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621

✉ info@rossari.com

🌐 www.rossari.com



## Rossari Biotech Limited

**Corporate Office:** Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai – 400079, Maharashtra, India

### Rossari Biotech announces Q4 & FY25 results

<u>Q4 FY25</u>	<u>FY25</u>
Revenue stood at Rs. 579.6 Cr EBITDA at Rs. 69.5 Cr PAT at Rs. 34.4 Cr	Revenue at Rs. 2,080.3 Cr EBITDA stood at Rs. 265.1 Cr PAT at Rs. 136.4 Cr

**Mumbai, April 25, 2025:** Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended March 31, 2025.

### Consolidated: Q4 FY25 performance overview compared with Q4 FY24

- Revenue from operations grew 22.6% to Rs. 579.6 crore as compared to Rs. 472.7 crore
- EBITDA improved by 9.3% to Rs. 69.5 crore from Rs. 63.6 crore
  - o EBITDA margin at 12.0% as against 13.5%
- PAT increased by 0.9% to Rs. 34.4 crore from Rs. 34.1 crore
- EPS (Diluted) stood at Rs. 6.21\* as against Rs. 6.17\*

### Consolidated: FY25 performance overview compared with FY24

- Revenue from operations stood at Rs. 2,080.3 crore as against Rs. 1,830.6 crore, up 13.7%
- EBITDA increased by 6.1% to Rs. 265.1 crore as against Rs. 249.8 crore
  - o EBITDA margin at 12.7% as against 13.6%
- PAT higher by 4.4% to Rs. 136.4 crore as against Rs. 130.7 crore
- EPS (Diluted) stood at Rs. 24.63 as against Rs. 23.62

#### Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
- 2) \* EPS not annualized

**Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said**

*"We concluded the year with a steady performance, navigating a soft and evolving operating environment. Revenues grew by ~14% driven by healthy export momentum and resilient volumes across key categories. The HPPC segment remained the primary growth driver, supported by deeper market penetration and strong traction across agrochemicals, personal care, institutional and consumer business. The TSC and AHN segments recorded modest revenue growth, contributing positively to the overall performance. We remain optimistic about their medium-to-long-term potential, supported by ongoing portfolio optimization efforts.*

*Export markets continued to perform well during the year, validating our strategic investments in global partnerships and differentiated solutions. We are also encouraged by the growing momentum in emerging verticals such as institutional cleaning and B2C businesses, which reflect our ability to build scalable, value-added platforms aligned with evolving customer needs.*

*We continue to invest in capacity enhancement to strengthen our growth foundation and are pleased to announce an additional capex of Rs. 97 crore for expansions at our subsidiaries, Unitop Chemicals and Tristar Intermediates, along with Rs. 95 crore at Rossari Biotech. These projects, expected to be commissioned in a phased manner by Q4 FY26, are aimed at supporting growth across our key chemistries, improving operational efficiency, and enhancing supply reliability. Our previously announced expansion projects are progressing well, with commissioning expected by Q2 FY26. With these capacity additions, we are well-positioned to meet growing demand across end-user industries.*

*Looking ahead, we remain focused on delivering sustainable, profitable growth through sharp execution, customer-centric innovation, and strategic diversification. Supported by a strong balance sheet, an agile business model, and a growing global footprint, we are confident in our ability to maintain healthy growth momentum in the coming years."*

## Key Developments

---

### Capex initiatives to strengthen growth capabilities

- Additional capex of Rs. 192 crore announced for capacity expansion at Rossari and subsidiaries: Rossari to expand by 13,000 MTPA; Unitop to add 18,500 MTPA; Tristar to expand by 3,600 MTPA
- Projects aimed at supporting growth across key chemistries, enhancing supply reliability, and improving operational efficiency
- Previously announced expansion projects are progressing as per revised schedule, with commissioning expected by Q2 FY26
- Combined, these initiatives position the Company to capitalise on rising demand across existing verticals

### Strong export momentum and global expansion

- Export performance remained exceptional in FY2025, driven by robust demand across key geographies
- Sales presence expanded to 70+ countries, reinforcing the Company's reach in key international markets
- Continued focus on cultivating demand across geographies through high-performance, value-added platforms

### Announces annual dividend of Re. 0.50 per share

- For FY 2024-25, the Board of Directors recommended a dividend of Re. 0.50 per share

**Note:** Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN)

**< Ends >**

### About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

---

For more information, please visit [www.rossari.com](http://www.rossari.com) OR contact:

---

**Ketan Sablok**

Rossari Biotech Limited  
Tel: +91 22 6123 3800  
Email: [ketan.sablok@rossari.com](mailto:ketan.sablok@rossari.com)

**Anoop Poojari / Mitesh Jain**

CDR India  
Tel: +91 98330 90434 / 96194 44691  
Email: [anoop@cdr-india.com](mailto:anoop@cdr-india.com) /  
[mitesh@cdr-india.com](mailto:mitesh@cdr-india.com)

---

### DISCLAIMER:

*Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.*